Clinical Trials Focus Valis Bioscience specializes in psychiatric and neurological trials, including schizophrenia, depression, anxiety, bipolar disorder, Parkinson’s disease, and Alzheimer’s disease, with experience in psychedelic compounds for PTSD and other conditions. This presents opportunities to cross-sell 21 CFR Part 11 compliant video recording, eCOA, PRO, and central review solutions to pharma companies running CNS and psychedelic-related trials.

Rare and Orphan Expertise The firm has deployed video review and monitoring capabilities specifically for rare and orphan studies, indicating a strength in handling complex, smaller populations and regulated data. This positions Valis to target sponsors seeking compliant, scalable review and data validation workflows for niche indications.

Integrated Solutions Valis offers a combined suite of consulting, data validation, scale development, and licensing, along with a broad product line from video systems to transcription and LMS. This all-in-one approach can be pitched to sponsors looking to streamline vendor management and consolidate CRO/tech needs into a single partner.

Technology Edge With 21 CFR Part 11 compliant video recording, machine-learning backed transcription, API access to Pearson assessments, and eCOA offerings, Valis demonstrates a modern technology stack suitable for large-scale digital trials. This can be leveraged to upsell digital endpoints, remote monitoring capabilities, and data interoperability enhancements.

Financial/Size Fit Revenue range of $10M–$25M and a lean employee base (11–50) suggest Valis is agile and services niche markets efficiently. Target mid-size biotech and specialty pharma companies looking for cost-effective CNS trial support, with scalable services that align with their growth stages.